199 related articles for article (PubMed ID: 25491733)
1. Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study.
Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
J Subst Abuse Treat; 2015 Apr; 51():82-90. PubMed ID: 25491733
[TBL] [Abstract][Full Text] [Related]
2. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood - a naturalistic long-term follow-up study.
Dalsgaard S; Mortensen PB; Frydenberg M; Thomsen PH
Addict Behav; 2014 Jan; 39(1):325-8. PubMed ID: 24090624
[TBL] [Abstract][Full Text] [Related]
3. Skills training groups for men with ADHD in compulsory care due to substance use disorder: a feasibility study.
Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
Atten Defic Hyperact Disord; 2016 Sep; 8(3):159-72. PubMed ID: 27059489
[TBL] [Abstract][Full Text] [Related]
4. Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder.
Tamm L; Trello-Rishel K; Riggs P; Nakonezny PA; Acosta M; Bailey G; Winhusen T
J Subst Abuse Treat; 2013 Feb; 44(2):224-30. PubMed ID: 22889694
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD.
Torgersen T; Gjervan B; Rasmussen K; Vaaler A; Nordahl HM
Atten Defic Hyperact Disord; 2013 Mar; 5(1):59-67. PubMed ID: 23104523
[TBL] [Abstract][Full Text] [Related]
6. Attention deficit/hyperactivity disorders with co-existing substance use disorder is characterized by early antisocial behaviour and poor cognitive skills.
Bihlar Muld B; Jokinen J; Bölte S; Hirvikoski T
BMC Psychiatry; 2013 Dec; 13():336. PubMed ID: 24330331
[TBL] [Abstract][Full Text] [Related]
7. Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications.
Schubiner H
CNS Drugs; 2005; 19(8):643-55. PubMed ID: 16097847
[TBL] [Abstract][Full Text] [Related]
8. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
Upadhyaya HP
J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study.
Torgersen T; Gjervan B; Nordahl HM; Rasmussen K
J Clin Psychopharmacol; 2012 Oct; 32(5):645-52. PubMed ID: 22926598
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
[TBL] [Abstract][Full Text] [Related]
12. Treatment seeking adults with autism or ADHD and co-morbid substance use disorder: prevalence, risk factors and functional disability.
Sizoo B; van den Brink W; Koeter M; Gorissen van Eenige M; van Wijngaarden-Cremers P; van der Gaag RJ
Drug Alcohol Depend; 2010 Feb; 107(1):44-50. PubMed ID: 19786328
[TBL] [Abstract][Full Text] [Related]
13. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder.
Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V
Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
15. The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review.
Schubiner H; Tzelepis A; Isaacson JH; Warbasse LH; Zacharek M; Musial J
J Clin Psychiatry; 1995 Apr; 56(4):146-50. PubMed ID: 7713853
[TBL] [Abstract][Full Text] [Related]
16. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.
van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and characteristics of South African treatment-seeking patients with substance use disorder and co-occurring attention-deficit/hyperactivity disorder.
Coetzee C; Truter I; Meyer A
Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1271-1280. PubMed ID: 33040639
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
19. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study.
Dalsgaard S; Østergaard SD; Leckman JF; Mortensen PB; Pedersen MG
Lancet; 2015 May; 385(9983):2190-6. PubMed ID: 25726514
[TBL] [Abstract][Full Text] [Related]
20. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder.
Riggs PD; Leon SL; Mikulich SK; Pottle LC
J Am Acad Child Adolesc Psychiatry; 1998 Dec; 37(12):1271-8. PubMed ID: 9847499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
